3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Active not recruiting
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
2
Non Small Cell Lung Cancer NSCLC
1
Lung Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Carboplatin
18
Cisplatin
14
pembrolizumab
13
durvalumab
11
Pemetrexed
11
Paclitaxel
11
Nivolumab
11
Gemcitabine
11
Rituximab
9
trastuzumab deruxtecan
7
osimertinib
6
olaparib
6
Dexamethasone
6
Capecitabine
6
atezolizumab
5
acalabrutinib
5
Specimen Handling
5
Lenalidomide
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
tremelimumab
4
niraparib
4
cabozantinib
4
amivantamab
4
Prednisone
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fulvestrant
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Active not recruiting
×
Has announcements
×
tremelimumab
×
Clear all
NCT03043872
2026-04-22
CASPIAN
AstraZeneca
Phase 3
Active not recruiting
987 enrolled
42 charts
1 FDA
NCT03298451
2026-03-20
HIMALAYA
AstraZeneca
Phase 3
Active not recruiting
1,324 enrolled
31 charts
1 FDA
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA
NCT03703297
2025-11-21
ADRIATIC
AstraZeneca
Phase 3
Active not recruiting
730 enrolled
19 charts
1 FDA